Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 2;222(6):e20241215.
doi: 10.1084/jem.20241215. Epub 2025 Apr 15.

Human immunity to fungal infections

Affiliations
Review

Human immunity to fungal infections

Donald C Vinh. J Exp Med. .

Abstract

Fungi increasingly threaten health globally. Mycoses range from life-threatening, often iatrogenic conditions, to enigmatic syndromes occurring without apparent immunosuppression. Despite some recent advances in antifungal drug development, complementary therapeutic strategies are essential for addressing these opportunistic pathogens. One promising avenue is leveraging host immunity to combat fungal infections; this necessitates deeper understanding of the molecular immunology of human fungal susceptibility to differentiate beneficial versus harmful immunopathological responses. Investigating human models of fungal diseases in natural settings, particularly through genetic immunodeficiencies and ethnographic-specific genetic vulnerabilities, reveals crucial immune pathways essential for fighting various yeasts and molds. This review highlights the diversity in intrinsic fungal susceptibility across individuals and populations, through genetic- and autoantibody-mediated processes, complementing previous principles learned from animal studies and iatrogenic contexts. Improved understanding of human immunity to fungal diseases will facilitate the development of host-directed immunotherapies and targeted public health interventions, paving the way for precision medicine in fungal disease management.

PubMed Disclaimer

Conflict of interest statement

Disclosures: D.C. Vinh reported other from Fonds de Recherche du Québec—Santé (FRQS); grants from the Public Health Agency of Canada/COVID Immunity Task Force, the Jeffrey Modell Foundation, and the Canadian Institutes of Health Research; personal fees from Merck Canada, Moderna, Qu Biologics, and Takeda; and other from McGill University Health Center Foundation: SDR Project outside the submitted work. In addition, D.C. Vinh has a patent pending (ID: 40101099 pending).

Similar articles

References

    1. Abolhassani, H., El-Sherbiny Y.M., Arumugakani G., Carter C., Richards S., Lawless D., Wood P., Buckland M., Heydarzadeh M., Aghamohammadi A., et al. . 2020. Expanding clinical phenotype and novel insights into the pathogenesis of ICOS deficiency. J. Clin. Immunol. 40:277–288. 10.1007/s10875-019-00735-z - DOI - PMC - PubMed
    1. Aichele, D., Schnare M., Saake M., Röllinghoff M., and Gessner A.. 2006. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients. Infect. Immun. 74:4708–4714. 10.1128/IAI.02066-05 - DOI - PMC - PubMed
    1. Al-Saud, B.K., Al-Sum Z., Alassiri H., Al-Ghonaium A., Al-Muhsen S., Al-Dhekri H., Arnaout R., Alsmadi O., Borrero E., Abu-Staiteh A., et al. . 2013. Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. J. Clin. Immunol. 33:1325–1335. 10.1007/s10875-013-9951-9 - DOI - PubMed
    1. Al-Tamemi, S., Alhinai Z., Al-Rahbi N., Al-Abdawani R., Al-Yazidi L., Al-Shekaili J., Al-Kindi M., and Al-Maawali A.. 2022. BCL10 loss-of-function novel mutation leading to atypical severe combined immunodeficiency. Clin. Immunol. 241:109067. 10.1016/j.clim.2022.109067 - DOI - PubMed
    1. Alsaidalani, A.A., García-Solís B., Bukhari E., Van Den Rym A., López-Collazo E., Sánchez-Ramón S., Corvillo F., López-Lera A., de Andrés A., Martínez-Barricarte R., and Perez de Diego R.. 2023. Inherited human BCL10 deficiencies. J. Clin. Immunol. 44:13. 10.1007/s10875-023-01619-z - DOI - PMC - PubMed

LinkOut - more resources